Simple serum.

Results to be presented at the AACR annual meeting this week indicate that, in a large prospective cohort, the simple serum test Gaurdant 360 detects actionable non-small cell lung cancer (NSCLC) mutations in all patients in whom a tissue biopsy detected one...plus a few more. Plus it had nearly half the turn-around time. | Papadimitrakopoulou, AACR 2019